Spots Global Cancer Trial Database for Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Official Title: High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation
Study ID: NCT02294552
Study Description
Brief Summary: This study evaluates the efficacy of high-dose post-transplantation cyclophosphomide as graft-versus-host disease (GVHD) prophylaxis after allogeneic stem cell transplantation in patients with different risk of GVHD. The risk-adapted strategy involves using single-agent cyclophosphomide in recipients of matched bone marrow graft, and combining cyclophosphomide with tacrolimus and mycophenolate mofetil in recipients of matched peripheral blood stem cells and mismatched bone marrow.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, , Russian Federation
Contact Details
Name: Boris V Afanasyev, MD, Prof.
Affiliation: First Pavlov State Medical University of St. Petersburg
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
